What is aids
Reading File
Searching the Web
AIDS acquired immunodeficiency syndrome overview 2025
Finding Sources
Reading File
Finding Sources
Reading File
Here is a thorough explanation of AIDS, drawing from Harrison's Principles of Internal Medicine (2025) and other authoritative medical textbooks:
AIDS (Acquired Immunodeficiency Syndrome)
What Is AIDS?
AIDS is the most advanced stage (Stage 3) of infection with the Human Immunodeficiency Virus (HIV) - an RNA retrovirus. It is defined clinically when:
- The CD4+ T cell count falls below 200 cells/µL (in persons >5 years of age), OR
- An AIDS-defining opportunistic illness or cancer develops
A healthy person has a CD4+ count of roughly 500-1,500 cells/µL. When it falls below 200, the immune system is so compromised that normally harmless organisms can cause life-threatening infections.
How HIV Causes AIDS
HIV attacks the immune system in a specific, stepwise way:
- Entry: The HIV envelope contains glycoprotein gp120, which binds to CD4 molecules on helper T cells. A co-receptor (CCR5 or CXCR4) is also required for entry.
- Fusion: Another glycoprotein, gp41, anchors the virus into the T-cell membrane, allowing viral RNA and reverse transcriptase to enter the cell.
- Integration: The viral enzyme reverse transcriptase converts single-stranded viral RNA into DNA, which is integrated into the host genome as a provirus (via the enzyme integrase).
- Replication: The infected T cell produces new HIV particles, which are released and infect more CD4+ T cells.
- Immune response: Cytotoxic CD8+ T cells destroy HIV-infected CD4+ T cells, further reducing helper T-cell numbers.
- Depletion: Over time (often years), CD4+ counts fall progressively. When they drop below 200/µL, the body can no longer mount effective immune responses, and AIDS results.
The incubation period from HIV infection to clinical AIDS can be up to 11 years without treatment.
Stages of HIV Infection
| Stage | Description |
|---|---|
| Stage 0 | Early/acute infection; negative test within 6 months of HIV diagnosis |
| Stage 1 | CD4 count ≥ 500 cells/µL; no AIDS-defining illness |
| Stage 2 | CD4 count 200-499 cells/µL |
| Stage 3 (AIDS) | CD4 count < 200 cells/µL OR AIDS-defining illness |
| Unknown | Insufficient information |
Opportunistic Infections and AIDS-Defining Illnesses
With a severely weakened immune system, people with AIDS become vulnerable to infections and cancers that healthy individuals fight off easily. Common examples include:
- Infections: Pneumocystis jirovecii pneumonia (PCP), tuberculosis, CMV retinitis, cryptococcal meningitis, toxoplasmosis
- Cancers: Kaposi's sarcoma, non-Hodgkin lymphoma, invasive cervical cancer
- Other: Wasting syndrome, HIV encephalopathy
Transmission
HIV (and therefore AIDS) spreads through:
- Unprotected sexual contact
- Sharing of contaminated needles or syringes
- Blood transfusions (with infected blood)
- Mother to child (during birth or breastfeeding)
HIV is not spread through casual contact (hugging, coughing, sharing utensils, etc.).
Treatment
AIDS is managed with Antiretroviral Therapy (ART) - a combination of drugs targeting different stages of the HIV lifecycle:
- NRTIs (nucleoside reverse transcriptase inhibitors) - e.g., tenofovir, emtricitabine
- NNRTIs (non-nucleoside reverse transcriptase inhibitors)
- Protease inhibitors - block viral protein processing
- Integrase strand transfer inhibitors (INSTIs) - e.g., dolutegravir, bictegravir; prevent viral DNA integration
- Current preferred regimens (2025) include bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir + TAF/FTC
ART does not cure HIV, but it:
- Suppresses viral replication to undetectable levels
- Allows CD4 counts to recover
- Prevents progression to AIDS
- Dramatically extends life expectancy - a 20-year-old on ART can expect to live 50+ more years (Harrison's, 2025 edition)
Global Burden
- ~39 million people are living with HIV worldwide
- Without treatment, AIDS remains fatal
- Funding challenges as of 2025 (including US aid cuts) threaten progress in global HIV control, particularly in sub-Saharan Africa
- New long-acting injectable therapies (e.g., lenacapavir, a capsid inhibitor given every 6 months) represent a major advancement in treatment and prevention
Sources: Histology: A Text and Atlas (9781975181512) | Harrison's Principles of Internal Medicine, 22nd Ed. (2025) | Tintinalli's Emergency Medicine
How to diagnose and monitor
Finding Sources
Finding Sources
Searching the Web
HIV AIDS diagnosis monitoring guidelines 2025 CD4 viral load
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information from Harrison's (2025), Red Book, and NIH guidelines. Here is the full answer:
Diagnosing and Monitoring HIV/AIDS
PART 1: DIAGNOSIS
Screening Recommendation
The CDC recommends routine HIV screening as part of standard healthcare for all adults aged 13-64, and for anyone at increased risk regardless of age. Screening should also be offered at every pregnancy. The goal is to test as part of routine care, not just when risk factors are identified.
The Current CDC Testing Algorithm (4-Step)
Step 1 - Initial Screen: Fourth-Generation Antigen/Antibody Combo Immunoassay (EIA)
This is the recommended first test. It simultaneously detects:
- HIV-1 and HIV-2 antibodies (IgG/IgM)
- HIV-1 p24 antigen (detectable earlier than antibodies)
Sensitivity is >99.5%. Antibodies typically appear 3-12 weeks after infection. The fourth-generation assay can detect infection as early as 18 days post-exposure (p24 antigen window) vs. ~22 days for antibody-only tests.
A negative result on 4th-generation EIA effectively rules out HIV unless there is strong suspicion of very recent exposure (within the past 3 months).
Step 2 - If Initial Screen is Reactive: HIV-1/HIV-2 Antibody Differentiation Immunoassay
- Performed on the same or a new blood sample
- Distinguishes HIV-1 from HIV-2 infection
- A positive result here confirms the diagnosis of HIV-1 or HIV-2
- Western blot is no longer recommended as a confirmatory test (per current CDC guidance)
Step 3 - If Differentiation Assay is Negative or Indeterminate: Nucleic Acid Test (NAT / HIV-1 RNA)
- Detects HIV-1 RNA directly in the blood
- A positive NAT in the setting of a negative antibody test = acute HIV-1 infection (the window period before antibodies develop)
- Can detect infection as early as 12 days post-exposure
- Qualitative RNA assay detects down to 100 copies/mL; DNA PCR detects 1-10 proviral DNA copies
Step 4 - Special Situations
| Situation | Approach |
|---|---|
| Suspected acute infection | Go directly to NAT (antibodies not yet detectable) |
| End-stage AIDS | Antibody tests can be falsely negative; use NAT or p24 antigen test |
| Children <18 months | Maternal antibodies cross placenta and persist; use DNA PCR (qualitative), not antibody tests |
| HIV-2 suspicion | Order specific HIV-1/HIV-2 differentiation assay; standard NATs do NOT detect HIV-2 |
| Home testing | OraQuick (oral fluid) and home blood tests available; reactive results must be confirmed in a lab |
"Window Period" - Detection Timeline
| Test | Earliest Detection After Infection |
|---|---|
| Nucleic acid test (NAT/RNA) | ~12 days |
| p24 antigen (4th-gen EIA) | ~18 days |
| Antibody only (3rd-gen) | ~22 days |
| Antibody only (older tests) | Up to 3 months |
PART 2: MONITORING
Once diagnosed, two core laboratory markers are used to monitor HIV disease and treatment response:
1. CD4+ T Cell Count
The CD4 count measures the degree of immune damage and guides clinical decisions.
| CD4 Count | Significance |
|---|---|
| 500-1500 cells/µL | Normal range |
| <500 cells/µL | Immune compromise beginning |
| <200 cells/µL | AIDS definition; high risk of opportunistic infections; start PCP prophylaxis |
| <50 cells/µL | Severe AIDS; very high risk of CMV, MAC, cryptococcus |
Monitoring frequency (per NIH guidelines):
- At HIV diagnosis (baseline)
- Every 3 months after starting ART (first 2 years) if CD4 <300 cells/mm³
- Every 6 months if CD4 is ≥300 cells/mm³ on suppressive ART
- After 1-2 years with consistent viral suppression and CD4 >300: optional/as clinically indicated
2. HIV Viral Load (Plasma HIV-1 RNA)
The viral load measures the number of HIV RNA copies per mL of blood. It is the single most important indicator of ART effectiveness.
| Viral Load | Interpretation |
|---|---|
| >100,000 copies/mL | High - rapid progression risk |
| 10,000-100,000 copies/mL | Moderate |
| <1,000 copies/mL | Low |
| <200 copies/mL | Virologically suppressed |
| <50 copies/mL | "Undetectable" - treatment goal |
| >1,000 copies/mL on ART | Treatment failure - consider resistance testing and regimen change |
Monitoring frequency:
- At diagnosis (baseline)
- 2-4 weeks after starting or changing ART (to confirm response)
- Every 4-8 weeks until suppressed
- Every 3-4 months in the first 2 years of ART
- Every 6 months once stably suppressed for >2 years
Key principle: Undetectable = Untransmittable (U=U). A person with a consistently undetectable viral load cannot sexually transmit HIV to an HIV-negative partner.
3. Other Monitoring Tests (Done at Baseline and Periodically)
| Test | Purpose |
|---|---|
| Genotypic resistance testing | Before starting ART and at treatment failure; check for transmitted drug resistance |
| HLA-B*5701 | Before using abacavir (to prevent severe hypersensitivity) |
| CBC, metabolic panel, LFTs, renal function | Assess organ function and drug toxicity |
| Fasting lipids & glucose | Metabolic complications of ART |
| Hepatitis B & C serology | Co-infection common; affects ART choice |
| TB testing (TST or IGRA) | Latent TB reactivation risk is high in HIV |
| STI screening, PAP smear, ophthalmology | Preventive care for co-infections and complications |
| IL-6, D-dimer, sCD14 | High correlation with all-cause mortality (research/specialized use) |
4. Resistance Testing
- Genotypic assay: Most common; sequences HIV genes to identify resistance mutations
- Phenotypic assay: Measures actual drug susceptibility (used for complex resistance)
- Co-receptor tropism assay (Trofile): Required before using maraviroc (CCR5 antagonist) to confirm the patient harbors CCR5-tropic rather than CXCR4-tropic virus
Sources: Harrison's Principles of Internal Medicine, 22nd Ed. (2025) | Red Book 2021, Committee on Infectious Diseases | NIH/clinicalinfo.hiv.gov guidelines | NY State AIDS Institute
This is a shared conversation. Sign in to Orris to start your own chat.